Sanket Koul

Strait of Hormuz crisis poses threat to India's luxury housing market

Developers stare at delayed imports of key materials, higher costs of imports and potential delay in construction timelines

Parliamentary panel pulls up HealthMin over drug scheme funding gaps

Panel flags funding discontinuity in drug regulation scheme, urges swift SSDRS 2.0 approval and decentralisation of medical device clearances to ease bottlenecks and improve oversight

Medtech industry split over Centre's move on standard device testing fees

Medtech firms are split over draft norms on standardised testing fees, with some backing transparency and others warning of higher compliance burden for low-risk devices

Drug regulator may retain GMP relaxations in Schedule M for select products

DTAB recommends continuing GMP exemptions under revised Schedule M for disinfectants, medical gases and gelatin capsules, citing limited relevance of strict norms

CDSCO moves to fast-track foreign drug import approvals, cut delays

Regulator plans to cut delays by allowing direct submission of Form 40 applications to DCGI, aiming to improve efficiency in drug import approvals

Semaglutide generics hit Mounjaro sales, market share after patent expiry

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Dalcore to invest ₹500 cr in first YOO-branded residences in North India

Developer eyes a topline of Rs 1,450 cr, with units priced at Rs 10 cr and above

Signature Global reports 5% drop in Q4 sales bookings on weak demand

Realty firm reports decline in Gurugram demand as FY26 bookings fall 20% to Rs 8,220 crore, missing guidance, even as average realisation improves on premiumisation

Max Healthcare acquires 58.4% stake in Kalinga Hospital for ₹300 crore

Max Healthcare enters eastern India with Kalinga Hospital acquisition, adding 250 beds and expanding its network through a Rs 300 crore deal

India a very high-priority market, Fortis primary growth vehicle: IHH CEO

IHH Healthcare eyes aggressive India expansion via Fortis, focusing on bed capacity, clusters, and ambulatory care amid strong healthcare demand

Max Estates FY26 pre-sales dip slightly despite strong Q4 demand

Developer reports marginal dip in annual pre-sales, but Q4 bookings surge on new launches, with strong pipeline and steady collections supporting growth outlook

West Asia war: Pressure builds on developers to hike prices as costs rise

Rising construction costs raising margin pressures; timelines maybe pushed by 3-6 months; mid-to-small scale developers more impacted

US pharma tariffs: CDMOs with innovator exposure likely to take a hit

Branded, patented pharma companies that have not agreed to lower drug prices via MFN agreements will face 100 per cent tariffs

Firms with cancelled drug licences may face heat as Centre tightens rules

DCC discusses stricter norms to bar firms with cancelled licences from reapplying and proposes public disclosure of inspection findings to strengthen pharma regulation

Accenture leases 1.65 lakh sq ft office space in Noida for ₹195 crore

IT major signs five-year lease with Onward Coworkx in Noida, reflecting sustained demand for office space amid strong leasing activity in metro cities

Emcure slashes obesity drug Poviztra price by up to 55% amid competition

Emcure cuts Poviztra prices by up to 55% following Novo Nordisk's move, lowering monthly treatment costs for semaglutide-based obesity therapy in India

Medtech, pharma welcome duty relief, seek GST cuts on key inputs

Industry welcomes customs duty exemption on petrochemicals but urges GST relief on inputs and faster refunds to ease cost pressures amid West Asia disruptions

Mahagun Group secures ₹225 crore from CSL Finance to speed up delivery

Mahagun Group raises Rs 225 crore from CSL Finance to accelerate construction and improve liquidity, following its recent exit of Blackstone-backed ASK Property Fund

Indian drugmakers may lose up to $750 million if Iran war drags on

Indian pharmaceutical companies may face losses of up to $750 million if the West Asia conflict continues, amid supply chain disruptions and rising logistics costs

M3M to deploy ₹14,500 crore to fund construction of 45 mn sqft portfolio

M3M India plans to deploy ₹14,500 crore to accelerate construction of over 45 million sq ft, funded through internal accruals and working capital